<p>Di-<em>O</em>-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity</p>

Decitabine in myelodysplastic syndromes

Decitabine dosage in myelodysplastic syndromes

contained a chromosome 7 abnormality (also mostly monosomy 7). Four of 11 patients with complex karyotype including aberrations of chromosome 7 showed cytogenetic responses (Figure 1; Table 1) compared with 2 responders of 9 patients with complex karyotype not containing a chromosome 7 abnormality. This high response rate in patients with chromosome 7 abnormalities is in stark contrast to the n...

Mixed-phenotype acute leukemia treated with decitabine

Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. pISSN 1226-3303 eISSN 2005-664...

Low-dose decitabine and high-risk MDS.

Kantarjian et al1 present their randomized study of 3 schedules of low-dose decitabine in patients with higher-risk myelodysplastic syndrome/chronic monomyelocytic leukemia (MDS/CMML) reporting a high complete remission (CR) rate. This comprehensive clinical trial along with its biologic correlates represents a significant addition to the therapeutic choices available for patients with MDS. For...

Decitabine Induced Transient Cardiomyopathy: A Case Report

CASE REPORT A 75-yr-old gentleman, with a past medical history of diabetes mellitus and Acute Myeloid Leukemia presented to our emergency department with a chief complaint of exertional dyspnea and chest pain. A week prior to this visit, he had recieved a cycle of decitabine chemotherapy at 20 mg/metered square for ten days. This was his second cycle of decitabine. His out patient medications i...